Immunogenicity, Reactogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2016
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 29 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2011 Planned end date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 28 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.